Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Effect of valsartan on left ventricular anatomy and systolic function and aortic elasticity.

Khaodhiar L, Brennan AM, Lima C, Chan JL, Mantzoros CS, Manning WJ, Danias PG, Veves A.

Metabolism. 2009 May;58(5):682-8. doi: 10.1016/j.metabol.2009.01.009.

PMID:
19375592
2.

Valsartan improves resting skin blood flow in type 2 diabetic patients and reduces poly(adenosine diphosphate-ribose) polymerase activation.

Shrikhande G, Khaodhiar L, Scali S, Lima C, Hubbard M, Dudley K, Ganda O, Ferran C, Veves A.

J Vasc Surg. 2006 Apr;43(4):760-70; discussion 770-1.

3.
4.

Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.

Yang HY, Kao PF, Chen TH, Tomlinson B, Ko WC, Chan P.

J Clin Pharmacol. 2007 Mar;47(3):397-403.

PMID:
17322151
5.

Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.

Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC; HKVIN Study Group.

Am J Kidney Dis. 2006 May;47(5):751-60.

PMID:
16632013
6.

[Valsartan in patients with arterial hypertension and type 2 diabetes mellitus. The lapaval study].

Rodríguez Pérez JC, Novoa Novoa J, Caballero A, Anabitarte A, Plaza C, Palop L, Rodríguez Esparragón F.

Nefrologia. 2005;25(5):500-8. Spanish.

7.

Effect of raloxifene on aortic elasticity in healthy postmenopausal women.

Tritos NA, Goepfert L, Kissinger KV, Katsimaglis G, Manning WJ, Danias PG.

Am Heart J. 2005 Dec;150(6):1212.

PMID:
16338260
8.

Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.

Miyajima K, Minatoguchi S, Ito Y, Hukunishi M, Matsuno Y, Kakami M, Kawasaki M, Nishigaki K, Takemura G, Fujiwara H.

Hypertens Res. 2007 Apr;30(4):307-13.

PMID:
17541209
10.

Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study.

Duprez DA, Florea ND, Jones K, Cohn JN.

J Am Coll Cardiol. 2007 Aug 28;50(9):835-9. Epub 2007 Aug 13.

11.

Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy.

Suzuki K, Souda S, Ikarashi T, Kaneko S, Nakagawa O, Aizawa Y.

Diabetes Res Clin Pract. 2002 Sep;57(3):179-83.

PMID:
12126767
12.

Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.

Anand IS, Rector TS, Kuskowski M, Thomas S, Holwerda NJ, Cohn JN.

Circ Heart Fail. 2008 May;1(1):34-42. doi: 10.1161/CIRCHEARTFAILURE.107.736975.

13.

Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases.

Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Ando N, Ohta S, Yoshii M, Inada H, Tsukada K, Minami J, Ono H, Matsuoka H.

Hypertens Res. 2005 Nov;28(11):865-70.

PMID:
16555574
15.

Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial.

van der Bom T, Winter MM, Bouma BJ, Groenink M, Vliegen HW, Pieper PG, van Dijk AP, Sieswerda GT, Roos-Hesselink JW, Zwinderman AH, Mulder BJ.

Circulation. 2013 Jan 22;127(3):322-30. doi: 10.1161/CIRCULATIONAHA.112.135392. Epub 2012 Dec 17.

16.

The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension.

Saiki A, Ohira M, Endo K, Koide N, Oyama T, Murano T, Miyashita Y, Shirai K.

Diabetes Res Clin Pract. 2006 Dec;74(3):242-8. Epub 2006 May 19.

PMID:
16713009
17.

Valsartan for prevention of recurrent atrial fibrillation.

GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G, Tognoni G.

N Engl J Med. 2009 Apr 16;360(16):1606-17. doi: 10.1056/NEJMoa0805710. Erratum in: N Engl J Med. 2009 May 28;360(22):2379.

18.

Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).

Baruch L, Glazer RD, Aknay N, Vanhaecke J, Heywood JT, Anand I, Krum H, Hester A, Cohn JN.

Am Heart J. 2004 Dec;148(6):951-7.

PMID:
15632877
19.

Effects of valsartan on diabetic cardiomyopathy in rats with type 2 diabetes mellitus.

Yang ZH, Peng XD.

Chin Med J (Engl). 2010 Dec;123(24):3640-3.

PMID:
22166644
20.

Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.

Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.

Circulation. 2009 Oct 20;120(16):1577-84. doi: 10.1161/CIRCULATIONAHA.109.853648. Epub 2009 Oct 5.

Supplemental Content

Support Center